Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

Official title

Randomized Trial Comparing Immediate Versus Deferred Surgery for Symptomatic Epiretinal Membranes

Overview

Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surgery is performed earlier. In addition, there is a need to better understand predictors of outcomes when surgery is performed and predictors of progression when surgery is deferred. Finally, one of the most common presenting symptoms from an ERM is distortion or metamorphopsia. There are several objective measures of metamorphopsia but none have ever been employed to evaluate ERMs in a randomized clinical trial (RCT) and their usefulness is unknown. The purposes of this study are to better understand the optimal timing of surgery to produce the best visual result, to better understand predictors of outcomes in those who undergo surgery and predictors of progression in those whose are observed, and to better characterize and evaluate the usefulness of metamorphopsia and reading speed measures.

Interventions

• Procedure Immediate Vitrectomy
  Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
• Procedure Deferred Vitrectomy
  Vitrectomy may be performed only if at least one of the following criteria is met: 1. Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM 2. Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM a. Visits must be at least one month apart 3. Participant actively requests surgery due to worsening symptoms 4. Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-cl

Primary outcome measures

• Mean change in visual acuity letter score from baseline to 36 months [Time frame: Baseline to 36 months]

Eligibility criteria

Inclusion criteria

• Age ≥ 45 years
• E-ETDRS visual acuity 20/40 or better (≥69 letters)

o ERM must be thought to be the primary cause of vision loss

• ERM meeting the following criteria, according to the investigator

• ERM is not secondary to another condition
• Symptoms of visual loss and/or distortion (in the opinion of the investigator, the ERM is contributing to the participant's symptoms); either new or worsening in the past 24 months
• Epiretinal membrane involving or altering the central 3 mm of the macula on OCT
• Distortion within the central subfield due to ERM on OCT
• Immediate vitrectomy not required (investigator and participant are willing to wait at least 4 weeks to see if vision remains stable without having to proceed to vitrectomy)
• No known medical problems that will be a contraindication to surgery

Exclusion criteria

• History of retinal vascular disease
• History of vitreous hemorrhage if vitreous hemorrhage is thought to have caused the ERM

o History of vitreous hemorrhage is permitted provided the vitreous hemorrhage did not cause the ERM in the investigator's opinion

• History of inflammatory disease unless mild and completely resolved at least one year prior to randomization
• History of diabetic macular edema (DME), retinal vein occlusion (RVO), or uveitis (except mild uveitis that resolved >1 year prior to randomization)
• Prior intraocular surgery (except uncomplicated cataract extraction)
• Cataract extraction within prior 3 months
• Laser or cryosurgical retinopexy within one month of randomization
• Pneumatic retinopexy within one year of randomization
• Current untreated retinal tear or detachment

o A previously treated retinal tear with up to one disc diameter radius of subretinal fluid is permitted

• Macular hole
• Degenerative lamellar macular hole

o ERM foveoschisis ("tractional" lamellar hole) is permitted

• Vitreomacular traction within 1,500 microns of foveal center
• Central serous chorioretinopathy
• Nonproliferative diabetic retinopathy or worse (DR severity >20)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Treatment

Study locations

United States · 47 centers

• Mayo Clinic Arizona — Scottsdale
• Kent W. Small, MD, AMC — Glendale
• Salehi Retina Institute Inc. — Huntington Beach
• Loma Linda University — Loma Linda
• Retina Vitreous Associates, Northern California Retina Vitreous Assoc Medical Group, Inc. — Mountain View
• East Bay Retina Consultants, Inc. — Oakland
• Regents of the University of California, Davis, DBA University of California, Davis — Sacramento
• Macula Retina Vitreous Institute — Torrance
• … and 39 more centers

United Kingdom · 1 center

• South Tyneside and Sunderland NHS Trust — Sunderland

Identifiers

NCT: NCT05145491 · DRCR.net Protocol AM · UG1EY014231

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗